Tozorakimab
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease[1].
Product Specifications
CAS Number
2376858-66-9
Product Name Alternative
MEDI-3506
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tozorakimab.html
Purity
98.82
Solubility
H2O
Smiles
[Tozorakimab]
Molecular Weight
(144.66 kDa)
References & Citations
[1]Reid F, et al. Safety, pharmacokinetics and immunogenicity of the anti-interleukin-33 antibody, tozorakimab: results of a phase 1 study in healthy adults and patients with chronic obstructive pulmonary disease. American Thoracic Society. 2022: A2398-A2398. |[2]England E, et al. Tozorakimab (MEDI3506) : an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. Sci Rep. 2023 Jun 17;13 (1) :9825.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![NRG1 Mouse Monoclonal Antibody [Clone ID: OTI3B6]](https://cdn.genprice.uk/products/937/68dd1b89061270361ea219c8/imageurl/ta815271s.webp)